CY1122117T1 - Ενεργοποιηση μιας ανοσοαποκρισης - Google Patents

Ενεργοποιηση μιας ανοσοαποκρισης

Info

Publication number
CY1122117T1
CY1122117T1 CY20191100920T CY191100920T CY1122117T1 CY 1122117 T1 CY1122117 T1 CY 1122117T1 CY 20191100920 T CY20191100920 T CY 20191100920T CY 191100920 T CY191100920 T CY 191100920T CY 1122117 T1 CY1122117 T1 CY 1122117T1
Authority
CY
Cyprus
Prior art keywords
variant
invariant chain
activation
peptide
immune response
Prior art date
Application number
CY20191100920T
Other languages
English (en)
Inventor
Peter Holst
Allan Thomsen
Jan Christensen
Mirjana Grujic
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CY1122117T1 publication Critical patent/CY1122117T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχεται μεταξύ άλλων ένα κατασκεύασμα νουκλεϊκού οξέος, το οποίο περιλαμβάνει αλληλουχίες που κωδικεύουν α) τουλάχιστον μια αμετάβλητη αλυσίδας ή παράλλαγμα αυτής λειτουργικά συνδεδεμένη σε β) τουλάχιστον μια αντιγονική πρωτεΐνη ή πεπτίδιο ή ένα αντιγονικό θραύσμα της αναφερθείσας πρωτεΐνης ή πεπτιδίου, όπου το αναφερθέν κατασκεύασμα νουκλεϊκού οξέος χρησιμοποιείται για την ενεργοποίηση ενός εμβολίου για τον καρκίνο, και/ή η αναφερθείσα αμετάβλητη αλυσίδα ή παράλλαγμα αυτής δεν περιλαμβάνει τα πρώτα 17 αμινοξέα, και/ή η αναφερθείσα αμετάβλητη αλυσίδα ή παράλλαγμα αυτής δεν περιλαμβάνει τα LRMK υπολείμματα αμινοξέων της KEY περιοχής, και/ή η αναφερθείσα αμετάβλητη αλυσίδα περιλαμβάνει ένα παράλλαγμα της CLIP περιοχής.
CY20191100920T 2008-11-21 2019-09-02 Ενεργοποιηση μιας ανοσοαποκρισης CY1122117T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801638 2008-11-21
PCT/DK2009/050310 WO2010057501A1 (en) 2008-11-21 2009-11-20 Priming of an immune response
EP09760468A EP2355842A1 (en) 2008-11-21 2009-11-20 Priming of an immune response

Publications (1)

Publication Number Publication Date
CY1122117T1 true CY1122117T1 (el) 2020-11-25

Family

ID=40823418

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100920T CY1122117T1 (el) 2008-11-21 2019-09-02 Ενεργοποιηση μιας ανοσοαποκρισης

Country Status (20)

Country Link
US (4) US20110293704A1 (el)
EP (3) EP2865387B1 (el)
JP (4) JP2012509071A (el)
CN (3) CN102292102A (el)
AU (1) AU2009317691A1 (el)
BR (1) BRPI0921927B8 (el)
CA (1) CA2743229A1 (el)
CY (1) CY1122117T1 (el)
DK (1) DK2865387T3 (el)
ES (1) ES2743677T3 (el)
HK (1) HK1209645A1 (el)
HR (1) HRP20191594T1 (el)
HU (1) HUE045093T2 (el)
IL (4) IL212914A0 (el)
LT (1) LT2865387T (el)
PL (1) PL2865387T3 (el)
PT (1) PT2865387T (el)
RU (2) RU2017138373A (el)
SI (1) SI2865387T1 (el)
WO (1) WO2010057501A1 (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103345A2 (en) 2007-02-19 2008-08-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
BR112012030794B1 (pt) * 2010-06-04 2019-11-26 Inserm ( Institut National De La Santé Et De La Recherche Médicale) Novos compostos imunoadjuvantes e usos dos mesmos
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
BR112014013082B1 (pt) 2011-12-07 2021-02-02 Singapore Volition Pte Limited uso de um aduto nucleossomo-proteína e métodos para detectar a presença de um aduto nucleossomo-proteína
JP6373836B2 (ja) * 2012-07-26 2018-08-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
RU2733424C2 (ru) 2013-08-21 2020-10-01 Куревак Аг Способ повышения экспрессии кодируемых рнк белков
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
SG11201605260VA (en) * 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
US11623001B2 (en) 2015-10-12 2023-04-11 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201704417D0 (en) * 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
EP3703744A1 (en) * 2017-11-03 2020-09-09 Nouscom AG Vaccine t cell enhancer
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN108285885A (zh) * 2017-12-28 2018-07-17 中国农业大学 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用
EP3807298A1 (en) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
CA3109541A1 (en) * 2018-10-19 2020-04-23 Nouscom Ag Teleost invariant chain cancer vaccine
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US587673A (en) 1897-08-03 higgins
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JP2682061B2 (ja) 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
WO1997049430A1 (en) * 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CN101321781B (zh) * 2005-11-30 2018-06-29 哥本哈根大学 一种核苷酸疫苗
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2010027973A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use

Also Published As

Publication number Publication date
IL233175A0 (en) 2014-07-31
BRPI0921927B1 (pt) 2021-06-15
HK1209645A1 (en) 2016-04-08
JP2012509071A (ja) 2012-04-19
EP2865387A3 (en) 2016-02-24
US20150056227A1 (en) 2015-02-26
JP6825036B2 (ja) 2021-02-03
EP2865387A2 (en) 2015-04-29
CA2743229A1 (en) 2010-05-27
EP3552622A2 (en) 2019-10-16
EP3552622A3 (en) 2019-12-04
US20210386842A1 (en) 2021-12-16
EP2865387B1 (en) 2019-06-12
HRP20191594T1 (hr) 2019-11-29
US20110293704A1 (en) 2011-12-01
IL233174A0 (en) 2014-08-03
ES2743677T3 (es) 2020-02-20
JP2019146588A (ja) 2019-09-05
JP2015061530A (ja) 2015-04-02
CN104404068A (zh) 2015-03-11
EP2355842A1 (en) 2011-08-17
RU2017138373A (ru) 2019-02-11
BRPI0921927A2 (pt) 2016-04-26
SI2865387T1 (sl) 2019-10-30
HUE045093T2 (hu) 2019-12-30
PL2865387T3 (pl) 2019-12-31
IL212914A0 (en) 2011-07-31
IL233176A0 (en) 2014-07-31
BRPI0921927B8 (pt) 2021-08-31
RU2011125306A (ru) 2012-12-27
AU2009317691A1 (en) 2010-05-27
JP2017131220A (ja) 2017-08-03
LT2865387T (lt) 2019-09-25
WO2010057501A1 (en) 2010-05-27
CN102292102A (zh) 2011-12-21
DK2865387T3 (da) 2019-08-26
PT2865387T (pt) 2019-09-27
CN107090472A (zh) 2017-08-25
US20170290898A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
CY1122117T1 (el) Ενεργοποιηση μιας ανοσοαποκρισης
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
PE20100738A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
PE20050727A1 (es) Anticuerpos dirigidos a c-met
PE20071055A1 (es) Anticuerpos anti mn
BR112022025653A2 (pt) Vacina autoamplificante de rna sars-cov-2
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
EA200801735A1 (ru) Антиамилоидные иммуногенные композиции, способы и применения
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).